Trial
NCT02086513
Phase I Trial of LDE225 for Steroid-refractory Chronic GVHD After Allogeneic HSCT
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Massachusetts General Hospital
Collaborators
Novartis
Condition
Graft Versus Host Disease
Intervention
LDE225
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-03-19